Prognostic impact of morphometric nuclear grade of endometrial carcinoma

Cancer

Volumn 83, Issue 5, 1998, Pages 956-964

  Salvesen, Helga B ^a,b   Iversen, Ole Erik ^b   Akslen, Lars A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

DNA index; Endometrial carcinoma; Histologic grade; Histologic type; Nuclear morphometry; Ploidy; Prognosis; Stage

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ACANTHOMA; ADENOSQUAMOUS CARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; DNA DETERMINATION; ENDOMETRIUM CARCINOMA; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CARCINOMA, ADENOSQUAMOUS; CELL NUCLEUS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; METAPLASIA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 0032169882     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<956::AID-CNCR22>3.0.CO;2-T     Document Type: Article

References (41)

1. Mikuta JJ. International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer 1993;71: 1460-3.
2. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis: annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 1989;28:189-93.
3. Abeler VM, Kjoslash;rstad KE. Endometrial adenocarcinoma in Norway: a study of a total population. Cancer 1991;67:3093-103.
4. Creasman WT. New gynecologic cancer staging. Obstet Gynecol 1990;75:287-8.
5. Nordström B, Strang P, Bergström R, Nilsson S, Tribukait B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Cancer 1996; 78:1942-51.
6. Iversen OE. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 1986;155:770-6.
7. Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 1997;104:1302-7.
8. Salvesen HB, Akslen LA, Albrektsen G, Iversen OE. Poorer survival of nulliparous women with endometrial carcinoma. Cancer 1998;82:1328-33.
9. Zaino R, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial carcinoma. Cancer 1996;77:1115-21.
10. Rotman M, Aziz H, Halpern J, Schwartz D, Sohn C, Choi K. Endometrial carcinoma. Influence of prognostic factors on radiation management. Cancer 1993;71:1471-9.
11. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335: 640-9.
12. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85:729-34.
13. Soong R, Knowles S, Williams KE, hammond IG, Wysocki SJ, Iacopetta BJ. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996;74:562-7.
14. Salvesen HB, Iversen OE, Akslen LA. Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer 1998;77(7):1140-44.
15. Carriaga MT, Henson DE. The histologic grading of cancer. Cancer 1995;75:406-21.
16. Mittal KR, Schwartz PE, Barwick KW. Architectural (FIGO) grading, nuclear grading, and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high risk and low risk groups. Cancer 1988;61:538-45.
17. Zaino RJ, Silverberg SG, Norris HJ, Bundy BN, Morrow CP, Okagagi T. The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma: a gynecologic oncology group study. Int J Gynecol Pathol 1994;13:29-36.
18. FIGO stages, 1988 revision. Gynecol Oncol 1989;35:125-7.
19. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological typing of female genital tract tumours. World Health Organization. International histological classification of tumours. 2nd edition. Berlin: Springer-Verlag, 1994.
20. Nordström B, Strang P, Lindgren A, Bergström R, Tribukait B. Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? Int J Gynecol Pathol 1996;15:191-201.
21. Nedregaard L, Jacobsen M, Andersen JE. Interobserver agreement for tumour type, grade of differentiation and stage in endometrial carcinomas. Cancer 1995;79:944-51.
22. Baak JPA. Manual of quantitative pathology in cancer diagnosis and prognosis. 1st edition. Berlin: Springer-Verlag, 1991.
23. VanDiest PJ, Baak JPA. The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients. Hum Pathol 1991;22:326-30.
24. Ropponen K, Eskelinen M, Kosma VM, Lipponen P, Paakkinen P, Alhava E. Comparison of classic and quantitative prognostic factors in colorectal cancer. Anticancer Res 1996; 16:3875-82.
25. Fukuzawa S, Hashimura T, Sasaki M, Yamabe H, Yoshida O. Nuclear morphometry for improved prediction of the prognosis of human bladder carcinoma. Cancer 1995;76:1790-6.
26. Nativ O, Sabo E, Raviv G, Medalia O, Moskovitz B, Goldwasse B. The role of nuclear morphometry for predicting disease outcome in patients with localized renal cell carcinoma. Cancer 1995;76:1440-4.
27. Van der Putten HWHM, Baak JPA, Koenders TJM, Kurver PH, Stolk HG, Stolte LAM. Endometrial hyperplasia and stage I endometrial adenocarcinoma. Cancer 1989;63:1378-87.
28. Sorbe B, Risberg B, Thornthwaite J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer 1994;4:94-100.
29. Fleege JC, VanDiest PJ, Baak JPA. Systematic random sampling for selective interactive nuclear morphometry in breast cancer sections. Refinement and multiobserver evaluation. Anal Quant Cytol Histol 1993;15:281-9.
30. Iversen OE, Utaaker E, Skaarland E. DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1988;67: 531-7.
31. Utaaker E, Iversen OE, Skaarland E. The distribution and prognostic implications of steroid receptors in endometrial carcinomas. Gynecol Oncol 1987;28:89-100.
32. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34:187-220.
33. Norusis MJ. SPSS advanced statistics 6.1. Chicago: SPSS Inc., 1994.
34. Abeler VM, Kjoslash;rstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 1992;2:9-22.
35. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6: 93-108.
36. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 1995;14:30-8.
37. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham IE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035-41.
38. Podratz KC, Wilson TO, Gaffey TA, Cha SS, Katzmann JA. Deoxyribonucleic acid analysis fascilitates the pretreatment identification of high-risk endometrial cancer patients. Am J Obstet Gynecol 1993;168:1206-15.
39. Susini T, Rapi S, Savino L, Boddi V, Berti P, Massi G. Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: comparison with other clinical-pathologic parameters. Am J Obstet Gynecol 1994;170:527-34.
40. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial carcinoma. Cancer 1994;73:2380-5.
41. Strang P, Nordström B, Nilsson S, Bergström R, Tribukait B. Mutant p53 protein as a predictor of survival in endometrial carcinoma. Eur J Cancer 1996;32A:598-602.